For patients with triple negative breast cancer, currently undergoing neoadjuvant dd AC, would you consider adding pembrolizumab to weekly paclitaxel based on recent KEYNOTE-522 and continue as adjuvant?  

I think the decision should be informed by the degree of response to AC and initial bulk of disease at presentation. In patients who complete the AC portion and still have clinical evidence of substantial residual disease, I would absolutely consider adding pembrolizumab and carboplatin to weekly pa...

There are large differences between GeparNuevo and KEYNOTE-522. GeparNuevo is a phase 2 study with only 174 patients, using nab-paclitaxel without carbo and with dose dense anthracycline regimen. KEYNOTE is a phase 3 study with 1,174 patients, using paclitaxel/carbo and q3week-anthracycline regimen....